Brainsway Receives New Buy Rating: 20‑30% Upside on TMS Growth

Brainsway Ltd. Receives Fresh Buy Rating Amid Optimistic TMS Outlook

Analyst Endorsements Strengthen Investor Confidence

On July 20, 2026, BTIG announced a buy rating for Brainsway Ltd. (NASDAQ: BRWS) following an encouraging assessment of the company’s transcranial magnetic stimulation (TMS) growth prospects. The recommendation comes on the back of a series of analyst endorsements that have re‑affirmed the stock’s potential in the near term.

In mid‑July, H.C. Wainwright reiterated both a $14 price target and a buy rating for Brainsway. The firm highlighted the company’s established commercial pipeline and robust market positioning in the treatment of major depressive disorder (MDD) and obsessive‑compulsive disorder (OCD). Wainwright’s commentary, published in both English and German feeds (www.investing.com and de.investing.com), underscored confidence that Brainsway’s neuromodulation platform will continue to capture increasing market share as indications expand and regulatory approvals mature.

Market Context

Brainsway’s shares, listed on the Tel Aviv Stock Exchange, closed at 4,635 ILA on July 16, 2026, reflecting a steady upward trajectory from its 52‑week low of 1,962 ILA in July 2025. The company’s market capitalization stands at approximately 610 million ILA, and its price‑earnings ratio sits around 69.56—a figure that signals a valuation driven by growth expectations rather than current earnings performance.

Forward‑Looking Outlook

With the latest analyst support, Brainsway’s valuation is now aligned with a mid‑term price target that suggests a 20‑30 % upside from current levels. The buy rating, coupled with a reaffirmed $14 target, positions the stock favorably for investors seeking exposure to the expanding non‑invasive neuromodulation space. Analysts anticipate that incremental product approvals and continued clinical success will further propel Brainsway’s revenue trajectory.

In summary, the convergence of BTIG’s buy recommendation and H.C. Wainwright’s consistent target and rating signals a bullish stance on Brainsway’s strategic positioning and growth potential in the health‑care equipment and supplies sector.